Keywords
How to Cite
Abstract
Myxoinflammatory fibroblastic sarcoma is a rare neoplasm, typically located in the distal portion of the extremities (hands and feet), which clinically presents as a painless, slow-growing mass. Microscopically, the variable proportion of its different components (spindle cell, inflammatory, bizarre multinucleated giant cells and myxoid component) means that very different differential diagnoses can be considered, from an inflammatory-infectious process to a lymphoproliferative one or a sarcomatous neoplasm. We present the case of a 53-year-old woman with a scapular subcutaneous nodule and her different histological differential diagnoses.
References
Montgomery EA, Devaney KO, Giordano TJ, Weiss SW (1998) Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin’s disease, and various sarcomas. Mod Pathol 11:384–391.
Meis-Kindblom JM, Kindblom LG (1998) Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol 22:911–924.
Michal M. Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 1998; 194 (8): 529.
Numminen J, Bizaki A, Kujansivu J, Huovinen S, Rautiainen M. Myxoinflammatory fibroblastic sarcoma of the nose: first reported case at an unusual location (nasal dorsum), with a review of the literature. Ear Nose Throat J. (2016) 3:E32–5.
Auw-Haedrich C, Mentzel T, Reinhard T. Myxoinflammatory fibroblastic sarcoma of the iris. Pathology. (2017) 7:794–5.
Jain E, Kini L, Alaggio R, Ranganathan S. Myxoinflammatory fibroblastic sarcoma of eyeball in an infant: a rare presentation. Int J Surg Pathol. (2020) 3:306–9.
Wei C, Yang X, Guo P, Chen X, Li C, Chen J, et al. Myxoinflammatory fibroblastic sarcoma of the parotid gland: First case report and literature review. Front Med (Lausanne). 2022; 9.
McFarlane R, Meyers AD, Golitz L. Myxoinflammatory fibroblastic sarcoma of the neck. J Cutan Pathol. 2005 May;32(5):375-8.
BlueBooksOnlineWho.int. https://tumourclassification.iarc.who.int/chaptercontent/64/244.
Laskin WB, Fetsch JF, Miettinen M. Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome. Am J Surg Pathol. 2014 Jan; 38(1):1-12.
Sakaki M, Hirokawa M, Wakatsuki S, Sano T, Endo K, Fujii Y et al (2003) Acral myxoinflammatory fibroblastic sarcoma: a report of five cases and review of the literature. Virchows Arch 442:25–30.
Kurmar S, Lefkowitz RA, Neto AD (2017). Myxoinflammatory fibroblastic sarcoma: clinical, imaging, management and outcome in 29 patients.
Hassanein, A.M., Atkinson, S.P., Al-Quran, S.Z., Jain, S.M. and Reith, J.D. (2008), Acral myxoinflammatory fibroblastic sarcomas: are they all low-grade neoplasms?. Journal of Cutaneous Pathology, 35: 186-191.
Lambert I, Debiec-Rychter M, Guelinckx P, Hagemeijer A, Sciot R (2001) Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch 438:509–512.
Ieremia E, Thway K. Myxoinflammatory fibroblastic sarcoma: morphologic and genetic updates. Arch Pathol Lab Med. 2014 Oct;138(10):1406-11.
Mansoor A, Fidda N, Himoe E, Payne M, Lawce H, Magenis RE (2004) Myxoinflammatory fibroblastic sarcoma with complex supernumerary ring chromosomes composed of chromosome 3 segments. Cancer Genet Cytogenet 152:61–65.
Suster D, Michal M, Huang H, Ronen S, Springborn S, Debiec-Rychter M, Billings SD, Goldblum JR, Rubin BP, Michal M, Suster S, Mackinnon AC. Myxoinflammatory fibroblastic sarcoma: an immunohistochemical and molecular genetic study of 73 cases. Mod Pathol. 2020 Dec;33(12):2520-2533.
Arbajian E, Hofvander J, Magnusson L, Mertens F. Deep sequencing of myxoinflammatory fibroblastic sarcoma. Genes Chromosomes Cancer. 2020 May;59(5):309-317.
Boland JM, Folpe AL. Hemosiderotic Fibrolipomatous Tumor, Pleomorphic Hyalinizing Angiectatic Tumor, and Myxoinflammatory Fibroblastic Sarcoma: Related or Not? Adv Anat Pathol. 2017 Sep;24(5):268-277.
Elco CP, Mariño-Enríquez A, Abraham JA, Dal Cin P, Hornick JL. Hybrid myxoinflammatory fibroblastic sarcoma/hemosiderotic fibrolipomatous tumor: report of a case providing further evidence for a pathogenetic link. Am J Surg Pathol. 2010 Nov;34(11):1723-7.
Zreik RT, Carter JM, Sukov WR, Ahrens WA, Fritchie KJ, Montgomery EA, Weiss SW, Folpe AL. TGFBR3 and MGEA5 rearrangements are much more common in "hybrid" hemosiderotic fibrolipomatous tumor-myxoinflammatory fibroblastic sarcomas than in classical myxoinflammatory fibroblastic sarcomas: a morphological and fluorescence in situ hybridization study. Hum Pathol. 2016 Jul;53:14-24.
Liu H, Sukov WR, Ro JY. The t(1;10)(p22;q24) TGFBR3/MGEA5 translocation in pleomorphic hyalinizing angiectatic tumor, myxoinflammatory fibroblastic sarcoma, and hemosiderotic fibrolipomatous tumor. Arch Pathol Lab Med. (2019) 2:212–21.
Antonescu CR, Zhang L, Nielsen GP, Rosenberg AE, Dal Cin P, Fletcher CD. Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor. Genes Chromosomes Cancer. 2011 Oct;50(10):757-64.
Kao YC, Ranucci V, Zhang L, Sung YS, Athanasian EA, Swanson D, Dickson BC, Antonescu CR. Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors. Am J Surg Pathol. 2017 Nov;41(11):1456-1465.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2024 Archives of Pathology